gms | German Medical Science

Patients and methods: This case series includes six patients with various ophthalmic complications, treated using regenerative therapies:

Case 1: A patient with corneal edema, endothelial cell loss, and epithelial erosion following hard nucleus phacoemulsification was treated with subconjunctival platelet concentrate injections and a hybrid PRF-AMSCs membrane.

Case 2: A young female developed microbial keratitis after corneal cross-linking for keratoconus. She received a single subconjunctival injection of 0.5 mL PRP combined with targeted antibiotic therapy.

Case 3: An 8-year-old boy with severe unilateral keratoconus-related hydrops was treated with 0.8 mL activated PRP and air bubbling in the anterior chamber.

Case 4: A patient with corneal edema after intraocular lens (IOL) exchange, unresponsive to conventional treatment for two months, received a subconjunctival 0.4 mL A-PRP injection.

Case 5: A 40-year-old male with recurrent pterygium underwent a bare sclera excision followed by PRF-MB sutured graft placement.

Case 6: A 60-year-old man with persistent ocular hypotony (IOP = 6 mmHg), resistant to conventional treatment, was treated with a 0.5 mL subconjunctival A-PRP injection.

Results: Regenerative treatments enhanced corneal healing, vision restoration, and ulcer resolution within 8–10 days. One case identified IOL-related edema, pterygium showed no recurrence after two years, and ocular hypotony improved with IOP reaching 13 mmHg in five days.

Conclusion: Outcomes are a combination of safe procedures. Autologous PRP and PRF membrane grafts enriched with ADMSCs provide an effective regenerative treatment for corneal impairment, enhancing healing through bioactive substances produced by thrombocytes. The promising outcomes observed in this case series highlight the potential of these therapies.